www.astro.org
Abstract # 2271 Long term Outcomes for Patients with Gleason Scores 8-10 Prostate Cancer Treated with Combination Brachytherapy, External Beam Irradiation and Hormonal Therapy

Presenter: Stock, Richard

< Back to topics

> Cover Page, Authors, Institutions

> Purpose/Objective

> Materials/Methods

> Results/Discussion

> Conclusions

> View tables/images/videos


Results:
The actuarial freedom from biochemical failure rates (FBF) at 10 years for all patients were 78% (ASTRO), 74% Phoenix (PHNX) and 66% (AUA (>0.2ng/ml)). Freedom from distant metastases at 10 years was 76%. In the 33 patients with biochemical failure (PHNX), the rate of developing distant metastases was 49% at 5 years and 78% by 10 years. Prostate cancer specific and overall survival at 10 years was 92% and 78%, respectively. There was a significant difference in 10 year FBF rates (PHNX) for patients with a Gleason score of 8 (84%) versus those with 9,10 (58%), p=0.002. Presenting PSA also had a significant impact with rates of 78% for patients with PSA < 20 ( PHNX) versus 58% for those with PSA > 20 (p=0.004). Higher BED values were associated with increased biochemical control. Patients with BED < 200 (71 patients) had a 10 year FBF rate of 66% versus 78.5% for those with BED > 200 (106 patients) (p=0.02). 31 patients underwent post‐treatment biopsy with 97% having negative biopsies. Last testosterone levels ranged from 10 to 826 (median ‐ 288). 64% had levels > 200.